◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Corgi Genomics & Precision Medicine ETF (GNMX) ETF Overview

Name: Corgi Genomics & Precision Medicine ETF (GNMX) price history and fund statistics
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

Price history, fund statistics and profile — an exchange-traded fund.

Exchange-Traded Funds · Health · DATA UPDATED 2026-08-31

Corgi Genomics & Precision Medicine ETF (GNMX) is an exchange-traded fund managed by Corgi Funds in the "Health" category. It manages roughly $2 million in assets.

The fund is an ETF that seeks to meet its objective by having Corgi Strategies, LLC actively manage the fund and, under ordinary market conditions, invest at least 80% of its net assets (plus any borrowings for investment purposes) in a portfolio of companies materially involved in the research, development, and commercialization of genomics and precision medicine technologies that enable improved disease detection, identifying and grouping patients based on genetic, molecular, or clinical characteristics to guide treatment decisions, targeted therapies, and data-driven healthcare.

Interactive chart & fund stats →

GNMX Fund Statistics

Expense ratio	0.35%
Assets under management	$2 million
Fund category	Health
Fund family	Corgi Funds
Inception	2026-05-05

The live price chart, fund profile and news are in the interactive GNMX viewer.

Other Companies in Health

MDEV · First Trust Indxx Global Medical Devices ETF — $3 million
WDNA · WisdomTree BioRevolution Fund — $3 million
HLTH · Tema Healthcare AI ETF — $2 million
LGHT · Langar Global Healthtech ETF — $2 million
ASD · Defiance Autism Impact ETF — $1 million
MHIP · Milliman Healthcare Inflation Plus ETF — $1 million
TRUH · Vaneck Healthcare TruSector ETF — $1 million
GSKH · GSK plc ADRhedged — $1 million

← GNMA All “G” companies GNOM →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.